



Please replace formula IIIaf on page 28 with the following rewritten formula:

C 17




Please replace formula IVo on page 32 with the following rewritten formula:

C 18




Please replace formula Vi on page 34 with the following rewritten formula:

C 19



Please replace formula Vt on page 36 with the following rewritten formula:


C 20



IN THE CLAIMS:

Please amend claims 11, 13, 14, 33, 34, 36, and 38, and enter new claims 41 and 42, as follows:

Sub P1
 11. (Amended) A method for providing sedation, mitigating anxiety or providing anaesthesia in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound, wherein the therapeutic compound is of the formula (Ia):




in which F^2 is an organic radical which may be joined in a cyclic ring system with G^2 , and which may contain inorganic counterions, but is not a nitrate group; E is a methylene group and G^1 is a methylene group or does not exist; F^1 is H ; and G^2 is R^N-Z^N ;

wherein R^N is an organic radical possessing a heteroaryl group containing P or S atoms where said P or S are positioned β , γ , or δ to a nitrate group as identified in formula I; and Z^N is $W^N_{mm}X^N_{nn}Y^N_{oo}$;

wherein mm , nn , oo are 0 or 1 and W^N, X^N, Y^N are NH , NR^{NN} , CO , O or CH_2 ;

wherein R^{NN} is a short chain alkyl group ($C_1 - C_{12}$).

Sub P2
 13. (Twice Amended) A method for providing sedation, mitigating anxiety or providing anaesthesia in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound, wherein the therapeutic compound is of the formula (Ic):



in which E is $(R^1R^2C)_m$ and $G^2-G^1-CF^1F^2-$ is $R^{19}-(R^3R^4C)_p-(R^{17}R^{18}C)_n-$;

wherein: m, n, p are integers from 0 to 10;

$R^{3,17}$ are each independently hydrogen, a nitrate group, or A; and

$R^{1,4}$ are each independently hydrogen, or A;

[initials]
 P.
 cont.

where A is selected from a substituted or unsubstituted aliphatic group (comprising a branched or straight-chain aliphatic moiety having from 1 to 24 carbon atoms in the chain, which optionally may contain O, S, NR⁶ and unsaturations in the chain, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; an unsubstituted or substituted cyclic aliphatic moiety having from 3 to 7 carbon atoms in the aliphatic ring, which optionally may contain O, S, NR⁶ and unsaturations in the ring, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; an unsubstituted or substituted aliphatic moiety constituting a linkage of from 0 to 5 carbons, between R¹ and R³ and/or between R¹⁷ and R⁴, which optionally may contain O, S, NR⁶ and unsaturations in the linkage, and optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups); a substituted or unsubstituted aliphatic group (comprising a branched, cyclic or straight-chain aliphatic moiety having from 1 to 24 carbon atoms in the chain) containing carbonyl linkages (C=O, C=S, C=NOH), which optionally may contain O, S, NR⁶ and unsaturations in the chain, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; a substituted or unsubstituted aryl group; a heterocyclic group; an amino group selected from alkylamino, dialkylamino, cyclic amino, diamino and triamino moieties, arylamino, diarylamino, and alkylarylamino; hydroxy, alkoxy, a substituted or unsubstituted aryloxy;

wherein X is F, Br, Cl, NO₂, CH₂, CF₂, O, NH, NMe, CN, NHOH, N₂H₃, N₂H₂R¹³, N₂HR¹³R¹⁴, N₃, S, SCN, SCN₂H₂(R¹⁵)₂, SCN₂H₃(R¹⁵), SC(O)N(R¹⁵)₂, SC(O)NHR¹⁵, SO₃M, SH, SR⁷, SO₂M, S(O)R⁸, S(O)₂R⁹, S(O)OR⁸, S(O)₂OR⁹, PO₂HM, PO₃HM, PO₃M₂, P(O)(OR¹⁵)(OR¹⁶), P(O)(OR¹⁶)(OM), P(O)(R¹⁵)(OR⁸), P(O)(OM)R¹⁵, CO₂M, CO₂H, CO₂R¹¹, C(O), C(O)R¹², C(O)(OR¹³), PO₂H, PO₂M, P(O)(OR¹⁴), P(O)(R¹³), SO, SO₂, C(O)(SR¹³), SR⁵, SSR⁷ or SSR⁵;

Y is F, Br, Cl, CH₃, CF₂H, CF₃, OH, NH₂, NHR⁶, NR⁶R⁷, CN, NHOH, N₂H₃, N₂H₂R¹³, N₂HR¹³R¹⁴, N₃, S, SCN, SCN₂H₂(R¹⁵)₂, SCN₂H₃(R¹⁵), SC(O)N(R¹⁵)₂, SC(O)NHR¹⁵, SO₃M, SH, SR⁷, SO₂M, S(O)R⁸, S(O)₂R⁹, S(O)OR⁸, S(O)₂OR⁹, PO₂HM, PO₃M₂, P(O)(OR¹⁵)(OR¹⁶), P(O)(OR¹⁶)(OM), P(O)(R¹⁵)(OR⁸), P(O)(OM)R¹⁵, CO₂M, CO₂H, CO₂R¹¹, C(O)R¹², C(O)(OR¹³), C(O)(SR¹³), SR⁵, SSR⁷ or SSR⁵, or does not exist;

R², R⁵, R¹⁸, R¹⁹ are optionally hydrogen, A or X-Y;

R⁶, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ are the same or different alkyl or acyl groups containing 1-24 carbon atoms which may contain 1-4 ONO₂ substituents; or C₁ - C₆ connections to R¹ - R⁴ in cyclic derivatives which may contain 1-4 ONO₂ substituents; or are each independently hydrogen, a nitrate group or A;

122 part 2 cont.
M is H, Na^+ , K^+ , NH_4^+ , $\text{N}^+\text{H}_k\text{R}^{11-k}$ where k is 0-3; or other pharmaceutically acceptable counterion;

cont. and with the proviso that when $m = n = p = 1$ and $\text{R}^{19}, \text{R}^2, \text{R}^{18}, \text{R}^1 = \text{H}$ and $\text{R}^{17}, \text{R}^3$ are nitrate groups, R^4 is not H.

14. (Amended) The method of claim 11, wherein F^2 is a nitrate group; and $\text{E}, \text{F}^1, \text{G}^1, \text{G}^2$ are the same or different organic radicals which may be joined in cyclic ring systems, and which may contain inorganic counterions;

with the proviso that when E and G^1 are methylene groups and F^1 is H, G^2 is not a nitrate group, nor R^NZ^N ;


wherein R^N is any aryl or heteroaryl group and Z^N is $(\text{O}\text{O})_{mm}\text{X}^N\text{nn}\text{Y}^N\text{oo}$;

wherein mm, nn, oo are 0 or 1 and X^N, Y^N are NH, NR^{NN}, O or CH₂;


wherein R^{NN} is a short chain alkyl group (C₁ - C₁₂).

33. (Amended) A method of providing sedation or mitigating anxiety in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound selected from the group consisting of:


IIIa




IIIb








IIIc




IIId







IIIj




IIIk




IIIl






C 24
Cont.







IIIm






IIIn















12
Cont.




124
cont.








124
125











34. (Amended) The method of claim 33, wherein the compound has the formula IIIt:








36. (Amended) A method of providing sedation or mitigating anxiety in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound selected from the group consisting of:




















38. (Amended) A method of mitigating anxiety in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound selected from the group consisting of:














C 2b
cont




126
cont'







Vu



Vv




Vw




126
Cont.


Vx







Vy





Vz





126

cont



, and

